Cardiac troponin T in pregnant women having intravenous tocolytic therapy
Language English Country Germany Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
10326630
DOI
10.1007/s004040050239
Knihovny.cz E-resources
- MeSH
- Apgar Score MeSH
- Adult MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Fenoterol adverse effects MeSH
- Fetal Blood chemistry MeSH
- Humans MeSH
- Infant, Newborn MeSH
- Pregnancy MeSH
- Body Weight MeSH
- Tocolysis adverse effects MeSH
- Pregnancy Trimester, Third MeSH
- Troponin T blood MeSH
- Verapamil adverse effects MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Infant, Newborn MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fenoterol MeSH
- Troponin T MeSH
- Verapamil MeSH
We studied drug-induced cardiotoxic effects in 22 pregnant women having tocolysis with intravenous fenoterol and verapamil. Because CK-MB is released from the uterus and placenta, we used the determination of cardiac troponin T (cTnT) as it is one of the most sensitive and specific indicators of myocardial necrosis. Cardiac troponin T levels were within physiological range (0.08 +/- 0.01 microgram/l) in all healthy pregnant women tested between 32 and 36 weeks of gestation (control group). In the pregnant women having tocolysis cTnT levels started to increase slightly during the first day of treatment (0.10 +/- 0.03 microgram/l) and were significantly higher (p < 0.05) during the third day (0.35 +/- 0.14 microgram/l) of tocolytic therapy. The cTnT levels in cord blood (0.13 +/- 0.03 microgram/l) did not correspond with maternal cTnT concentrations.
References provided by Crossref.org
Comprehensive review of cardiovascular toxicity of drugs and related agents
